Edgestream Partners, L.P. Nektar Therapeutics Transaction History

Edgestream Partners, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $84,361 - $415,217	-131,815 Reduced 21.65%	477,036 $333,000
Q4 2022 Feb 13, 2023	SELL	$2.03 - $4.28 $890,733 - $1.88 Million	-438,785 Reduced 41.88%	608,851 $1.38 Million
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $58,222 - $98,441	-19,152 Reduced 1.8%	1,047,636 $3.35 Million
Q2 2022 Aug 12, 2022	BUY	$3.17 - $6.17 $1.4 Million - $2.73 Million	443,081 Added 71.04%	1,066,788 $4.05 Million
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $2.43 Million - $8.01 Million	583,667 Added 1457.71%	623,707 $3.36 Million
Q4 2021 Feb 15, 2022	BUY	$10.83 - $18.41 $433,633 - $737,136	40,040 New	40,040 $541,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

Stay updated on Edgestream Partners, L.P. with notifications on news.